Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (51) 51
life sciences & biomedicine (41) 41
humans (27) 27
female (22) 22
ophthalmology (22) 22
male (19) 19
clinical trials (12) 12
visual acuity - physiology (12) 12
angiogenesis inhibitors - therapeutic use (10) 10
comparative analysis (9) 9
macular degeneration (9) 9
middle aged (9) 9
physical sciences (9) 9
technology (9) 9
tomography, optical coherence (9) 9
vascular endothelial growth factor a - antagonists & inhibitors (9) 9
aged (8) 8
aged, 80 and over (8) 8
antibodies, monoclonal, humanized - therapeutic use (8) 8
bevacizumab (8) 8
fluorescein angiography (8) 8
ranibizumab (8) 8
child, preschool (7) 7
cohort studies (7) 7
physiological aspects (7) 7
prospective studies (7) 7
analysis (6) 6
drug therapy (6) 6
risk factors (6) 6
wet macular degeneration - drug therapy (6) 6
chemistry (5) 5
genes (5) 5
intravitreal injections (5) 5
age related macular degeneration (4) 4
animals (4) 4
cross-sectional studies (4) 4
environmental sciences & ecology (4) 4
follow-up studies (4) 4
genotype (4) 4
incidence (4) 4
macular degeneration - drug therapy (4) 4
medical colleges (4) 4
medical research (4) 4
medicine, research & experimental (4) 4
pediatrics (4) 4
proteins (4) 4
research & experimental medicine (4) 4
studies (4) 4
wet macular degeneration - diagnosis (4) 4
amblyopia (3) 3
biochemistry & molecular biology (3) 3
biomarkers (3) 3
cell biology (3) 3
child (3) 3
china (3) 3
consulting services (3) 3
environmental sciences (3) 3
infant (3) 3
infant, newborn (3) 3
macula lutea - pathology (3) 3
macular degeneration - diagnosis (3) 3
medicine, experimental (3) 3
odds ratio (3) 3
patients (3) 3
physics (3) 3
polymorphism, single nucleotide (3) 3
retrospective studies (3) 3
science & technology - other topics (3) 3
treatment outcome (3) 3
vision tests (3) 3
wet macular degeneration - physiopathology (3) 3
216974-75-3 (2) 2
abridged index medicus (2) 2
amblyopia - complications (2) 2
amblyopia - diagnosis (2) 2
amblyopia - physiopathology (2) 2
angiogenesis inhibitors (2) 2
anisometropia - complications (2) 2
astigmatism (2) 2
bevacizumab - therapeutic use (2) 2
biomedical engineering (2) 2
biotechnology & applied microbiology (2) 2
cancer (2) 2
cell growth (2) 2
cell proliferation (2) 2
chemistry, analytical (2) 2
chemistry, multidisciplinary (2) 2
chemistry, physical (2) 2
choroidal neovascularization - drug therapy (2) 2
complement c3 - genetics (2) 2
complement factor h - genetics (2) 2
depth perception - physiology (2) 2
dose-response relationship, drug (2) 2
early childhood education (2) 2
ecology (2) 2
endothelial growth factors (2) 2
energy & fuels (2) 2
engineering (2) 2
enzyme-linked immunosorbent assay (2) 2
enzymes (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
by Grunwald, Juan E., MD and Daniel, Ebenezer, MBBS, MD and Huang, Jiayan, MS and Ying, Gui-shuang, PhD and Maguire, Maureen G., PhD and Toth, Cynthia A., MD and Jaffe, Glenn J., MD and Fine, Stuart L., MD and Blodi, Barbara, MD and Klein, Michael L., MD and Martin, Alison A and Hagstrom, Stephanie A., PhD and Martin, Daniel F., MD and CATT Research Group and CATT Res Grp
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2014, Volume 121, Issue 1, pp. 150 - 161
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Follow-Up Studies | Geographic Atrophy - diagnosis | Humans | Middle Aged | Geographic Atrophy - drug therapy | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Genotyping Techniques | Bevacizumab | Incidence | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Visual Acuity - physiology | Fluorescein Angiography | Geographic Atrophy - epidemiology | Wet Macular Degeneration - epidemiology | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Proportional Hazards Models | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Aged | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy | Risk factors | Biomedical engineering | Medical research | Medicine, Experimental | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
by Ying, Gui-shuang, PhD and Huang, Jiayan, MS and Maguire, Maureen G., PhD and Jaffe, Glenn J., MD and Grunwald, Juan E., MD and Toth, Cynthia, MD and Daniel, Ebenezer, MBBS, MS, MPH and Klein, Michael, MD and Pieramici, Dante, MD and Wells, John, MD and Martin, Daniel F., MD and Comparison of Age-related Macular Degeneration Treatments Trials Research Group and Comparison Age-Related Macular
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2013, Volume 120, Issue 1, pp. 122 - 129
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Intravitreal Injections | Tomography, Optical Coherence | Humans | Middle Aged | Male | Treatment Outcome | Wet Macular Degeneration - physiopathology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Wet Macular Degeneration - drug therapy | Time Factors | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Aged | Visual Acuity - physiology | Cohort Studies | Fluorescein Angiography | Macular degeneration | Physiological aspects | Medical colleges | Angiogenesis inhibitors | Consulting services | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-related Macular Degeneration Treatments Trials
by Sharma, Sumit, MD and Toth, Cynthia A., MD and Daniel, Ebenezer, MBBS, PhD and Grunwald, Juan E., MD and Maguire, Maureen G., PhD and Ying, Gui-Shuang, PhD and Huang, Jiayan, MS and Martin, Daniel F., MD and Jaffe, Glenn J., MD and Comparison of Age-related Macular Degeneration Treatments Trials Research Group and Comparison Age-Related Macular Deg
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2016, Volume 123, Issue 4, pp. 865 - 875
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Choroidal Neovascularization - diagnosis | Bevacizumab - therapeutic use | Prospective Studies | Intravitreal Injections | Geographic Atrophy - diagnosis | Humans | Male | Wet Macular Degeneration - physiopathology | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Retinal Pigment Epithelium - pathology | Choroidal Neovascularization - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Visual Acuity - physiology | Fluorescein Angiography | Macula Lutea - pathology | Tomography, Optical Coherence | Choroidal Neovascularization - physiopathology | Photography | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Subretinal Fluid | Aged | Cohort Studies | Macular degeneration | Clinical trials | Comparative analysis | Drug therapy | Fluorescein | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
by Jaffe, Glenn J., MD and Martin, Daniel F., MD and Toth, Cynthia A., MD and Daniel, Ebenezer, MPH, PhD and Maguire, Maureen G., PhD and Ying, Gui-Shuang, PhD and Grunwald, Juan E., MD and Huang, Jiayan, MS and Comparison of Age-related Macular Degeneration Treatments Trials Research Group and Comparison Age-related Macular
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2013, Volume 120, Issue 9, pp. 1860 - 1870
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Follow-Up Studies | Macular Degeneration - physiopathology | Tomography, Optical Coherence | Humans | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Bevacizumab | Ranibizumab | Subretinal Fluid | Angiogenesis Inhibitors - therapeutic use | Visual Acuity - physiology | Fluorescein Angiography | Macula Lutea - pathology | Macular degeneration | Clinical trials | Comparative analysis | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
by Daniel, Ebenezer, MBBS, PhD and Toth, Cynthia A., MD and Grunwald, Juan E., MD and Jaffe, Glenn J., MD and Martin, Daniel F., MD and Fine, Stuart L., MD and Huang, Jiayan, MS and Ying, Gui-shuang, MD, PhD and Hagstrom, Stephanie A., PhD and Winter, Katrina, BS and Maguire, Maureen G., PhD and Comparison of Age-related Macular Degeneration Treatments Trials Research Group and Comparison of Age-related Macular
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2014, Volume 121, Issue 3, pp. 656 - 666
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Cicatrix - etiology | Intravitreal Injections | Humans | Middle Aged | Male | Cicatrix - diagnosis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Wet Macular Degeneration - genetics | Bevacizumab | Incidence | Ranibizumab | Angiogenesis Inhibitors - therapeutic use | Female | Postoperative Complications | Visual Acuity - physiology | Fluorescein Angiography | Antibodies, Monoclonal, Humanized - therapeutic use | Tomography, Optical Coherence | Risk Factors | Genotype | Wet Macular Degeneration - diagnosis | Wet Macular Degeneration - drug therapy | Fibrosis | Retina - pathology | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Comparative analysis | Drug therapy | Risk factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Risk Factors for Amblyopia in the Vision in Preschoolers Study
by Pascual, Maisie, MS and Huang, Jiayan, MS and Maguire, Maureen G., PhD and Kulp, Marjean Taylor, OD, MS and Quinn, Graham E., MD, MSCE and Ciner, Elise, OD and Cyert, Lynn A., OD, PhD and Orel-Bixler, Deborah, OD, PhD and Moore, Bruce, OD and Ying, Gui-shuang, PhD and Vision In Preschoolers (VIP) Study Group and Vision Preschoolers VIP Study Grp
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2014, Volume 121, Issue 3, pp. 622 - 629.e1
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | United States - epidemiology | Vision Screening | Amblyopia - epidemiology | Amblyopia - etiology | Cross-Sectional Studies | Strabismus - complications | Refractive Errors - complications | Humans | Risk Factors | Child, Preschool | Male | Refractive Errors - epidemiology | Retinoscopy | Amblyopia - diagnosis | Strabismus - epidemiology | Vision, Ocular | Early Intervention (Education) | Female | Odds Ratio | Child | Visual Acuity - physiology | Medicine, Experimental | Medical research | Early childhood education | Risk factors | Amblyopia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT)
by Ying, Gui-shuang, PhD and Maguire, Maureen G., PhD and Daniel, Ebenezer, MBBS, PhD and Ferris, Frederick L., MD and Jaffe, Glenn J., MD and Grunwald, Juan E., MD and Toth, Cynthia A., MD and Huang, Jiayan, MS and Martin, Daniel F., MD and Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group and Comparison Age-Related Macular
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2015, Volume 122, Issue 12, pp. 2523 - 2531.e1
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Bevacizumab - therapeutic use | Prospective Studies | Bevacizumab - administration & dosage | Follow-Up Studies | Intravitreal Injections | Macular Degeneration - physiopathology | Tomography, Optical Coherence | Humans | Middle Aged | Male | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Angiogenesis Inhibitors - administration & dosage | Visual Acuity - drug effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Ranibizumab - administration & dosage | Aged | Visual Acuity - physiology | Fluorescein Angiography | Macular degeneration | Clinical trials | Comparative analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT)
by Hagstrom, Stephanie A., PhD and Ying, Gui-shuang, PhD and Pauer, Gayle J.T., BA and Sturgill-Short, Gwen M., BA and Huang, Jiayan, MS and Callanan, David G., MD and Kim, Ivana K., MD and Klein, Michael L., MD and Maguire, Maureen G., PhD and Martin, Daniel F., MD and Comparison of AMD Treatments Trials Research Group and Comparison AMD Treatments Trials R
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2013, Volume 120, Issue 3, pp. 593 - 599
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Humans | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - diagnosis | Macular Degeneration - drug therapy | Bevacizumab | Ranibizumab | Serine Endopeptidases - genetics | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Complement C3 - genetics | Visual Acuity - physiology | Fluorescein Angiography | Pharmacogenetics | Antibodies, Monoclonal, Humanized - therapeutic use | Tomography, Optical Coherence | Gene Frequency | High-Temperature Requirement A Serine Peptidase 1 | Genotype | Proteins - genetics | Macular Degeneration - genetics | Aged | Polymorphism, Single Nucleotide | Complement Factor H - genetics | Macular degeneration | Genes | Physiological aspects | Clinical trials | Genetic aspects | Angiogenesis inhibitors | Comparative analysis | Single nucleotide polymorphisms | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The effectiveness of mindfulness-based stress reduction (MBSR) for survivors of breast cancer: Study protocol for a randomized controlled trial
by Huang, Jiayan and Shi, Lu
Trials, ISSN 1745-6215, 04/2016, Volume 17, Issue 1, pp. 209 - 209
Mindfulness-based stress reduction | Compliance | Breast cancer survivor | Quality of life | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Stress, Psychological - prevention & control | Humans | Clinical Protocols | Cost of Illness | Anxiety - prevention & control | Mental Health | Stress, Psychological - psychology | Stress, Psychological - diagnosis | Breast Neoplasms - therapy | Depression - etiology | Psychiatric Status Rating Scales | Time Factors | China | Female | Survivors - psychology | Anxiety - psychology | Treatment Outcome | Mindfulness | Breast Neoplasms - complications | Medication Adherence | Pilot Projects | Depression - prevention & control | Breast Neoplasms - psychology | Depression - psychology | Quality of Life | Breast Neoplasms - diagnosis | Research Design | Self Care | Anxiety - etiology | Stress, Psychological - etiology | Care and treatment | Usage | Analysis | Mental health | Clinical trials | Stress management | Breast cancer | Index Medicus | Study Protocol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Compression and Aggregation-Resistant Particles of Crumpled Soft Sheets
by Luo, Jiayan and Jang, Hee Dong and Sun, Tao and Xiao, Li and He, Zhen and Katsoulidis, Alexandros P and Kanatzidis, Mercouri G and Gibson, J. Murray and Huang, Jiaxing
ACS nano, ISSN 1936-0851, 11/2011, Volume 5, Issue 11, pp. 8943 - 8949
graphene oxide | capillary compression | strain hardening | crumpling | graphene | aerosol | aggregation-resistant particles | Physical Sciences | Chemistry | Materials Science | Nanoscience & Nanotechnology | Technology | Materials Science, Multidisciplinary | Science & Technology - Other Topics | Chemistry, Multidisciplinary | Chemistry, Physical | Science & Technology | Solid state | Compressing | Graphene | Flats | Droplets | Nanostructure | Compressive strength | Materials processing | Surface area
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Incidence of Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials
by Maguire, Maureen G., PhD and Daniel, Ebenezer, MBBS, PhD and Shah, Ankoor R., MD and Grunwald, Juan E., MD and Hagstrom, Stephanie A., PhD and Avery, Robert L., MD and Huang, Jiayan, MS and Martin, Revell W., BA and Roth, Daniel B., MD and Castellarin, Alessandro A., MD and Bakri, Sophie J., MD and Fine, Stuart L., MD and Martin, Daniel F., MD and Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group) and Comparison Age-Related Macular
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2013, Volume 120, Issue 10, pp. 2035 - 2041
Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Choroidal Neovascularization - epidemiology | Intravitreal Injections | Humans | Middle Aged | Male | Macular Degeneration - drug therapy | Bevacizumab | Incidence | Dose-Response Relationship, Drug | Choroidal Neovascularization - drug therapy | Choroidal Neovascularization - pathology | Ranibizumab | Serine Endopeptidases - genetics | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Complement C3 - genetics | Genetic Predisposition to Disease | Antibodies, Monoclonal, Humanized - therapeutic use | Macular Degeneration - complications | High-Temperature Requirement A Serine Peptidase 1 | Genotype | Proteins - genetics | Macular Degeneration - genetics | Aged | Polymorphism, Single Nucleotide | Complement Factor H - genetics | Choroidal Neovascularization - genetics | Cohort Studies | Macular degeneration | Clinical trials | Physiological aspects | Neovascularization | Comparative analysis | Drug therapy | Consulting services | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights